PNC Financial Services Group’s Apogee Therapeutics APGE Stock Holding History

PNC Financial Services Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.8K	Buy	526 +416	+378%	+$37.5K	﹤0.01%	3144
2026 Q1	$9.26K	Buy	110 +28	+34%	+$2.03K	﹤0.01%	3991
2025 Q4	$6.19K	Buy	82 +1	+1%	+$63	﹤0.01%	4147
2025 Q3	$3.22K	Sell	81 -54	-40%	-$2.06K	﹤0.01%	4364
2025 Q2	$5.86K	Buy	135 +108	+400%	+$4.11K	﹤0.01%	4068
2025 Q1	$1.01K	Buy	+27	New	+$1.04K	﹤0.01%	4516
2024 Q3	–	Sell	-2	Closed	-$79	–	4779
2024 Q2	$79	Buy	+2	New	+$97	﹤0.01%	4723
2023 Q4	–	Sell	-48	Closed	-$1.02K	–	4619
2023 Q3	$1.02K	Buy	+48	New	+$1.06K	﹤0.01%	4363

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

PNC Financial Services Group's APGE Position: Q2 2026 in Review

PNC Financial Services Group increased its Apogee Therapeutics (APGE) stake by 378% in Q2 2026, buying an estimated $37.5K and bringing the position to 526 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3144.

PNC Financial Services Group first reported a position in APGE in Q3 2023 and has held it in 8 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

PNC Financial Services Group held 526 shares of Apogee Therapeutics worth $69.8K as of Q2 2026.
PNC Financial Services Group bought 416 Apogee Therapeutics shares in Q2 2026, an estimated $37.5K.
Apogee Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3144 holding.
PNC Financial Services Group first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 8 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.